Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 3/20 | 0.36 |
| ▸ | CYSLTR1 | Q9Y271 | 5/20 | 0.35 |
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | DRD3 | P35462 | 2/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD5 | P21918 | 1/20 | 0.32 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5613046 | 0.81 | PTGER4 (0.42) | PTGER4CYSLTR1CYSLTR2SLC22A12 | |
| SCHEMBL5604828 | 0.80 | PTGER4 (0.43) | PTGER4CYSLTR1CYSLTR2PIN1PTGER2 | |
| SCHEMBL7946133 | 0.67 | MGLL (0.36) | OPRM1OPRD1OPRK1 | |
| SCHEMBL6574958 | 0.62 | PTGER4 (0.39) | PTGER4PTGER2 | |
| SCHEMBL6574955 | 0.62 | PTGER4 (0.39) | PTGER4PTGER2 | |
| SCHEMBL6574951 | 0.62 | PTGER4 (0.39) | PTGER4PTGER2 | |
| SCHEMBL6574950 | 0.62 | PTGER4 (0.39) | PTGER4PTGER2 | |
| SCHEMBL7049372 | 0.61 | MGLL (0.44) | DRD2DRD3DRD1OPRM1OPRD1 | |
| SCHEMBL11711459 | 0.61 | FAAH (0.33) | PTGER4PTGER2 | |
| SCHEMBL647539 | 0.60 | PTGS2 (0.64) | DRD2DRD3DRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010009920-A1 | Estrogen agonist/antagonist and a prostaglandin or a prostaglandin agonist/antagonist | KE HUA ZHU (US) | 2001-07-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009920-A1 | Estrogen agonist/antagonist and a prostaglandin or a prostaglandin agonist/antagonist | PTGER1, PTGER2, PTGER4 | PTGER4 3/4885CYSLTR1 81/4885CYSLTR2 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.